Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Govt Deregulation Panel Tenders Prerequisites for Envisaged Mixed Care System
April 17, 2014
- MHLW to Mull Applying Mixed Care Scheme to Low Cost-Effective Drugs: Minister
April 17, 2014
- Govt Panel Members Pitch Yearly NHI Price Cut, 0.8 Trillion Yen Could’ve Been Pruned over 7 Years
April 17, 2014
- PAFSC’s First Committee to Review Canagliflozin, Japan’s 5th SGLT-2 Inhibitor
April 15, 2014
- Pharma Leaders Push Abe Govt to Permanently Introduce Key Premium, R&D Tax Credit
April 15, 2014
- MHLW Panel on Counterfeit Drugs Holds First Meeting
April 14, 2014
- MHLW Diovan Panel Finalizes Report following Fine-Tuning
April 14, 2014
- “Transparency Must Be Ensured” for Funding by Pharmas: Minister
April 14, 2014
- Number of High-Cost New Drugs to Be Reimbursed Under Fee-for-Service System: Chuikyo
April 14, 2014
- Japan NIH Will Have Research Topic-Based Units to Stem Sectionalism: Official
April 11, 2014
- Japanese NIH-Related Bills Clear Lower House
April 11, 2014
- 14-Day Prescription Limit to Be Ruled Out for Anti-HIV Drug Tivicay
April 11, 2014
- Official Says Health Ministry Will Notify Industry about Electronic Data Submissions around June
April 11, 2014
- Abe’s Govt, Pharma Leaders to Hold Public-Private Dialogue on April 14
April 10, 2014
- MHLW Says Additional Data Needed for OBLEAN Listing
April 10, 2014
- Chuikyo OKs Listing of 14 APIs including Japan’s First SGLT-2 Inhibitor
April 10, 2014
- PAFSC’s Committee Requires Face-to-Face Consultations for Sale of 25 OTC Drugs Including Allegra FX
April 10, 2014
- MHLW’s Study Committee on Clinical Research Systems to Hold 1st Meeting on April 17
April 10, 2014
- PMDA Announces Ongoing Evaluation of Benambax for Risk of Severe Bradycardia
April 9, 2014
- FPMAJ Not Giving Up on Perpetuation of Premium for New Drug Development: Committee Chair
April 9, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…